PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors.
Bronwen E ShawKaren L SyrjalaLynn E OnstadEric J ChowMary E FlowersHeather JimK Scott BakerSarah BuckleyDiane L FaircloughMary M HorowitzStephanie J LeePublished in: Cancer (2017)
Physical and mental symptoms and function in autologous and allogeneic HCT survivors can be adequately assessed with PROMIS-29 and PROMIS-GH. Cancer 2018;124:841-9. © 2017 American Cancer Society.